Evidence mapPaperPMID 30170852Full record

ArticleLancet (London, England)2018

Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data.

Evangelos K Oikonomou, Mohamed Marwan, Milind Y Desai, Jennifer Mancio, Alaa Alashi, Erika Hutt Centeno, Sheena Thomas, Laura Herdman, Christos P Kotanidis, Katharine E Thomas and 11 more

2 registry-linked trialsOpen access · hybridAbstract readValidation Study
In one paragraph

Article in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 590 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
590citing papers in PubMed, 2 pooled it
45.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07567378 not yet recruitingstarted 2026, after this paper: background citation

Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition Subcohort

Ran2026Enrolled30Registered outcomes14Posted comparisons0ConditionsAtrial Fibrillation (AF), Coronary Artery Disease, Diabetes (DM), Heart FailureArmsTirzepatide
Open the trial in the graph
NCT04547231 unknown statusnot on this mapstarted 2020, after this paper: background citation

Impact of Stenosis and Plaque Features in Coronary CT Angiography, Physiologic Assessment and Pharmacotherapy on the Clinical Outcomes After Invasive Coronary Angiography

TypeobservationalSponsorSeoul National University HospitalRan2020 to 2025Enrolled992ConditionsCoronary Artery DiseaseArmsFractional flow reserve, Coronary CT angiography
3 · Its place in the literature

Who cites it

590 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,040 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

530 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 3 countries.

Evangelos K OikonomouDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Mohamed MarwanDepartment of Cardiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Milind Y DesaiCleveland Clinic Heart and Vascular Institute, Cleveland, OH, USA.
Jennifer MancioDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Alaa AlashiCleveland Clinic Heart and Vascular Institute, Cleveland, OH, USA.
Erika Hutt CentenoCleveland Clinic Heart and Vascular Institute, Cleveland, OH, USA.
Sheena ThomasDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Laura HerdmanDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Christos P KotanidisDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Katharine E ThomasDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Brian P GriffinCleveland Clinic Heart and Vascular Institute, Cleveland, OH, USA.
Scott D FlammCleveland Clinic Heart and Vascular Institute, Cleveland, OH, USA.
Alexios S AntonopoulosDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Cheerag ShirodariaCardiology Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Caristo Diagnostics, Oxford, UK.
Nikant SabharwalCardiology Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
John DeanfieldUniversity College London Institute of Cardiovascular Science, London, UK.
Stefan NeubauerDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford Centre of Research Excellence, British Heart Foundation, Oxford, UK; Oxford Biomedical Research Centre, National Institute of Health Research, Oxford, UK.
Jemma C HopewellClinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Keith M ChannonDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford Centre of Research Excellence, British Heart Foundation, Oxford, UK; Oxford Biomedical Research Centre, National Institute of Health Research, Oxford, UK.
Stephan AchenbachDepartment of Cardiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Charalambos AntoniadesDivision of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; Oxford Centre of Research Excellence, British Heart Foundation, Oxford, UK; Oxford Biomedical Research Centre, National Institute of Health Research, Oxford, UK. Electronic address: antoniad@well.ox.ac.uk.
University of Oxford · GBCleveland Clinic · USFriedrich-Alexander-Universität Erlangen-Nürnberg · DEOxford University Hospitals NHS Trust · GBBritish Heart Foundation · GBNational Institute for Health Research · GBUniversity College London · GB

Funding

British Heart Foundation FS/14/55/30806British Heart Foundation RG/07/003/23133British Heart Foundation RG/12/5/29576British Heart Foundation RG/17/10/32859
6 · The paper itself

Abstract

backgroundCoronary artery inflammation inhibits adipogenesis in adjacent perivascular fat. A novel imaging biomarker-the perivascular fat attenuation index (FAI)-captures coronary inflammation by mapping spatial changes of perivascular fat attenuation on coronary computed tomography angiography (CTA). However, the ability of the perivascular FAI to predict clinical outcomes is unknown.

methodsIn the Cardiovascular RISk Prediction using Computed Tomography (CRISP-CT) study, we did a post-hoc analysis of outcome data gathered prospectively from two independent cohorts of consecutive patients undergoing coronary CTA in Erlangen, Germany (derivation cohort) and Cleveland, OH, USA (validation cohort). Perivascular fat attenuation mapping was done around the three major coronary arteries-the proximal right coronary artery, the left anterior descending artery, and the left circumflex artery. We assessed the prognostic value of perivascular fat attenuation mapping for all-cause and cardiac mortality in Cox regression models, adjusted for age, sex, cardiovascular risk factors, tube voltage, modified Duke coronary artery disease index, and number of coronary CTA-derived high-risk plaque features.

findingsBetween 2005 and 2009, 1872 participants in the derivation cohort underwent coronary CTA (median age 62 years [range 17-89]). Between 2008 and 2016, 2040 patients in the validation cohort had coronary CTA (median age 53 years [range 19-87]). Median follow-up was 72 months (range 51-109) in the derivation cohort and 54 months (range 4-105) in the validation cohort. In both cohorts, high perivascular FAI values around the proximal right coronary artery and left anterior descending artery (but not around the left circumflex artery) were predictive of all-cause and cardiac mortality and correlated strongly with each other. Therefore, the perivascular FAI measured around the right coronary artery was used as a representative biomarker of global coronary inflammation (for prediction of cardiac mortality, hazard ratio [HR] 2·15, 95% CI 1·33-3·48; p=0·0017 in the derivation cohort, and 2·06, 1·50-2·83; p<0·0001 in the validation cohort). The optimum cutoff for the perivascular FAI, above which there is a steep increase in cardiac mortality, was ascertained as -70·1 Hounsfield units (HU) or higher in the derivation cohort (HR 9·04, 95% CI 3·35-24·40; p<0·0001 for cardiac mortality; 2·55, 1·65-3·92; p<0·0001 for all-cause mortality). This cutoff was confirmed in the validation cohort (HR 5·62, 95% CI 2·90-10·88; p<0·0001 for cardiac mortality; 3·69, 2·26-6·02; p<0·0001 for all-cause mortality). Perivascular FAI improved risk discrimination in both cohorts, leading to significant reclassification for all-cause and cardiac mortality.

interpretationThe perivascular FAI enhances cardiac risk prediction and restratification over and above current state-of-the-art assessment in coronary CTA by providing a quantitative measure of coronary inflammation. High perivascular FAI values (cutoff ≥-70·1 HU) are an indicator of increased cardiac mortality and, therefore, could guide early targeted primary prevention and intensive secondary prevention in patients.

fundingBritish Heart Foundation, and the National Institute of Health Research Oxford Biomedical Research Centre.

Indexed as

AdipocytesAdipose TissueAdolescentAdultAgedAged, 80 and overComputed Tomography AngiographyCoronary AngiographyCoronary Artery DiseaseCoronary VesselsFemaleFollow-Up StudiesHumansImaging, Three-DimensionalMaleMiddle Aged

Identifiers

PMID30170852
PMCPMC6137540
OpenAlexW2888909234

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.